UNSPSC 51384301: Benzpiperylon

This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C22H25N3O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7NHY63BKIV, chemically known as 1,2-dihydro-2-(1-methyl-4-piperidinyl)-4-phenyl-5-(phenylmethyl)-3h-pyrazol-3-one but generally known as benzpiperylon, which bears US NIH Compound Identifier 24039. European Medicines Agency schedules Benzpiperylone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05765MIG.

UNSPSC 51384301 Benzpiperylon is a Commodity-tier code that maps nominally to a specific pharmaceutical ingredient but shows no recent state and local procurement activity aligned with that narrow definition. The recent opportunities tagged under this code involve naloxone procurement, direct-to-manufacturer prescription programs, and generic multi-source pharmaceutical supply contracts—all broader pharmaceutical supply and distribution work rather than benzpiperylon itself. State and local governments are using this code to solicit pharmaceuticals, over-the-counter products, and health-system drug procurement support, but the mismatch between the code's nominal scope and actual buying patterns suggests either misclassification in the issuing bodies' coding practices or that the code is functioning as a catchall for pharmaceutical acquisitions outside conventional generic-drug channels.

Recent activity spans Florida county health systems, Texas state health agencies, and multi-state cooperative purchasing programs. Seminole County, Florida issued IFB 60459723LAS in June 2026 for 1,900 units of naloxone and 800 safe drug deactivation systems annually through quarterly deliveries, with responses due July 26, 2023. The Texas Health and Human Services Commission posted RFI HHS0017013 in April 2026 to assess vendor capacity for direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager arrangements. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) issued RFP S1070000015802 in January 2026 for generic multi-source pharmaceuticals and OTC products across multiple state and local participants, with proposals due March 26, 2026 and contract effectiveness set for July 1, 2026. The geographic spread includes Florida, Texas, Minnesota, and Oregon, with multi-state cooperative purchasing providing the broadest reach. Vendors pursuing this code should verify with issuing bodies that benzpiperylon is the intended procurement category; if not, activity may cluster under higher-tier pharmaceutical family or segment codes instead.